Dr. Wes: Prasugrel and Dronedarone: Rough Roads to Approval.
Precisely when these drugs will be available to the general market is uncertain, but I suspect you’ll know when meals start showing up in cath labs and offices again.
Now that’s just plain funny right there!
These sound promising but with new drugs comes new costs and you know these ain’t going to be cheap. Plavix already strains the budget of many cardiac patients as Sanofi Aventis/BMS managed to evade it going generic for some time now, so I can’t begin to imagine how a newer version is going to make things any easier on those folks. One can hope that docs will weigh these issues when deciding which drug to put folks on, rather than going with the newest, most shiny toys on the market.
